These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma? Tanaka K; Sata M; Uchimura Y; Suzuki H; Tanikawa K Oncol Rep; 1998; 5(1):205-8. PubMed ID: 9458323 [TBL] [Abstract][Full Text] [Related]
25. The eradication of HCV. De Nicola S; Colombo M Minerva Gastroenterol Dietol; 2016 Mar; 62(1):63-75. PubMed ID: 26446686 [TBL] [Abstract][Full Text] [Related]
26. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Masuzaki R; Yoshida H; Omata M Oncology; 2010 Jul; 78 Suppl 1():17-23. PubMed ID: 20616579 [TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma and hepatitis C in the United States. El-Serag HB Hepatology; 2002 Nov; 36(5 Suppl 1):S74-83. PubMed ID: 12407579 [TBL] [Abstract][Full Text] [Related]
30. Prevention and treatment of hepatocellular carcinoma. Omata M; Yoshida H Liver Transpl; 2004 Feb; 10(2 Suppl 1):S111-4. PubMed ID: 14762850 [TBL] [Abstract][Full Text] [Related]
31. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. Lodato F; Mazzella G; Festi D; Azzaroli F; Colecchia A; Roda E World J Gastroenterol; 2006 Dec; 12(45):7239-49. PubMed ID: 17143937 [TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of HBV and HCV infection in hepatocellular carcinoma and chronic liver disease--an autopsy based study. Vaiphei K; Pal NS; Arora SK Indian J Pathol Microbiol; 2006 Jul; 49(3):357-61. PubMed ID: 17001884 [TBL] [Abstract][Full Text] [Related]
33. Prevention of hepatitis C virus-related hepatocellular carcinoma. Heathcote EJ Gastroenterology; 2004 Nov; 127(5 Suppl 1):S294-302. PubMed ID: 15508097 [TBL] [Abstract][Full Text] [Related]
34. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928 [TBL] [Abstract][Full Text] [Related]
35. Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma. Caselmann WH; Alt M J Hepatol; 1996; 24(2 Suppl):61-6. PubMed ID: 8836891 [TBL] [Abstract][Full Text] [Related]